Experts & Research

Treatment of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Agents: Sunitinib Phase III Status Recruiting Sponsor Abbisko Therapeutics Co, Ltd For further information please also consult ClinicalTrials.gov.   This is a Phase III Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor WHO…

Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnership E. Roets, K. Schuster, S. Bickley, M. Wartenberg, O. Gonzato, N. Fernandez, B. Kasper, K. Pilgermann, R. Wilson, N. Steeghs, W. T. A. van der Graaf, G. van Oortmerssen…

Centers with sarcoma expertise Management of sarcomas in specialist centres is associated with significant benefits for patients. Amongst those who have experience with sarcoma, it is undisputed that sarcoma should be treated by experts or in specialist centres, although evidence is limited. However, despite broad use, the terms ‘specialist centre’ or ‘expert centre’ are rarely…

Medical societies such as the European Society of Medical Oncology (ESMO) in Europe or the National Comprehensive Cancer Network (NCCN) create guidelines which outline the standards of care for different types of cancer – among them guidelines for soft tissue sarcoma, bone sarcoma and GIST. These guidelines provide recommendations about diagnosis, treatment and follow-up for…